Wednesday, July 8, 2026

Drug profile · INN

loxapine hydrochloride

loxapine hydrochloride (LOXITANE C) is a d2-like dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — loxapine hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.89

Quick answer

loxapine hydrochloride (LOXITANE C) is a d2-like dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN loxapine hydrochloride
Brand LOXITANE C
Mechanism D2-like dopamine receptor antagonist
Target D2-like dopamine receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

D2-like dopamine receptor antagonist

Primary target: D2-like dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. chlorpromazine hydrochloride D2-like dopamine receptor antagonist
  2. droperidol D2-like dopamine receptor antagonist
  3. haloperidol Serotonin 2a (5-HT2a) receptor antagonist
  4. haloperidol decanoate D2-like dopamine receptor inverse agonist
  5. haloperidol lactate Serotonin 2a (5-HT2a) receptor antagonist
  6. loxapine succinate D2-like dopamine receptor antagonist

Frequently asked questions

What is loxapine hydrochloride?

loxapine hydrochloride (LOXITANE C) is a d2-like dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for loxapine hydrochloride?

LOXITANE C is a marketed brand name for loxapine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of loxapine hydrochloride?

loxapine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.